amino acid sequence comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The structure in this final region contains long, aligned lamellae that alternate between ice crystals and ceramic walls. The faster a sample is frozen, the finer its solvent crystals (and its eventual macroporosity) will be. Within the SSZ, the normal speeds which are usable for colloidal templating are 10 – 100 mm s−1 leading to solvent crystals typically between 2 mm and 200 mm. Subsequent sublimation of the ice within the SSZ yields a green ceramic preform with porosity in a nearly exact replica of these ice crystals. The microstructure of a freeze-cast within the SSZ is defined by its wavelength (λ) which is the average thickness of a single ceramic wall plus its adjacent macropore. Several publications have reported the effects of solidification kinetics on the microstructures of freeze-cast materials. It has been shown that λ follows an empirical power-law relationship with solidification velocity (υ) (Eq. 2.14):
Assessing the Cardinals' pennant chances during 1957 spring training, manager Fred Hutchinson said, "We've got at least three pitchers capable of winning 20-Herm Wehmeier, Sam Jones, and Vinegar Bend Mizell. If a couple of them can do it, we'll make plenty of trouble." Mizell's fastball had slowed a bit in 1956, and it was even slower in 1957. He was giving up more home runs than he had before he joined the Army, and the Cardinals were worried about his weight and his windup motion. Mizell spent much of the early part of the season in the bullpen, and the Cardinals even attempted to send him to Houston, but they were unable to get him through waivers. They had him watch films of his pitching, not common practice at the time, to help him correct his mistakes. On July 18, he relieved Hoyt Wilhelm in the ninth inning with the Cardinals leading the Dodgers 9–4 and the bases loaded. He retired Duke Snider on a groundout but then walked Gino Cimoli to bring up Gil Hodges, a right-handed hitter. Though many managers would have inserted a right-hander in this situation, Hutchinson left Mizell in to face him, and Hodges hit a grand slam, tying the game, which the Cardinals eventually lost 10–9. The decision drew ire from St. Louis fans, and general manager Frank Lane and executive vice president Richard A.
=== Weight harnesses === When large amounts of weight are needed, a harness may be used to carry the load on the diver's shoulders, rather than around the waist, where it may tend to slip down into an uncomfortable position if the diver is working in a vertical posture, which is often the case. Sometimes this is a separate harness, worn under the safety harness, with pockets at the sides to carry the weights, and sometimes it is an integrated system, which carries the weight in pockets built into or externally attached to the safety harness. On the standard diving suit, the load of the weighting system was usually at least partly transferred to the corselet of the copper helmet, to directly counteract the helmet's buoyancy.
Sources: en.wikipedia.org
Litvinenko in 2006, and was suspected as a possible cause of Yasser Arafat's death, following exhumation and analysis of his corpse in 2012–2013. The radioisotope may also have been used to kill Yuri Shchekochikhin, Lecha Islamov and Roman Tsepov.
=== Health === In a February 2026 livestream, part of an interview with The New York Times, Peters listed substances that were part of his daily routine, including testosterone, Accutane, retatrutide, and nebivolol. He began taking testosterone shots at 14. He also told The New York Times that he suspects he is sterile after years of injecting himself with testosterone and alluded to not necessarily enjoying the act of sex. Declaring himself infertile in the past due to testosterone injections, Peters explained: "So it's just like a negative feedback loop when you're not needing to produce testosterone anymore because your body realizes, okay, we're getting it from an outside source." Peters has stated that he is on the autism spectrum, although he has not been professionally diagnosed. He shared in a June 29, 2026, tweet that he used to stalk strangers so he could study neurotypical human behavior:
When glucose is fermented, it enters glycolysis or the pentose phosphate pathway and is converted to pyruvate. From pyruvate, pathways branch out to form a number of end products (e.g. lactate). At several points, electrons are released and accepted by redox cofactors (NAD and ferredoxin). At later points, these cofactors donate electrons to their final acceptor and become oxidized. ATP is also formed at several points in the pathway.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.